Trial reportThe Journal of infection2006
Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.
Trial report in The Journal of infection, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00036166 (An Open-Label, Non-Comparative Study of FK463 for the Treatment of Invasive Aspergillosis), which is not on this map. Cited by 68 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-Label, Non-Comparative Study of FK463 for the Treatment of Invasive Aspergillosis
Who cites it
68 citing papers in PubMed, 9 syntheses or guidelines pooled it, 294 citations in OpenAlex.
- Guideline
- Pooled it
- Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Guideline
- JAID/JSC Guidelines for the Treatment of Respiratory Infectious Diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy - The JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committee Respiratory Infectious Disease WG.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2016Guideline
- Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2014Pooled it
- Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials.The Pediatric infectious disease journal · 2014Pooled it
- Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).Annals of hematology · 2014Guideline
- Antifungal therapy in children: an update.European journal of pediatrics · 2013Pooled it
- Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2009Guideline
- Micafungin versus Amphotericin B in treatment of invasive fungal infection in preterm neonates: a randomized control trial.Italian journal of pediatrics · 2025Trial
- Trial
- Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents.Antimicrobial agents and chemotherapy · 2015Trial
- Effectiveness of posaconazole as primary prophylaxis in allogeneic hematopoietic stem cell transplantation.International journal of hematology · 2026Article
- Triazoles Versus Echinocandins for the First-Line Treatment of Invasive Pulmonary Aspergillosis: A Propensity Score-Weighted Multicenter Study.Open forum infectious diseases · 2025Article
- ISCCM Position Statement on the Management of Invasive Fungal Infections in the Intensive Care Unit.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024Article
- Impact of Invasive Pulmonary Aspergillosis in Critically Ill Surgical Patients with or without Solid Organ Transplantation.Journal of clinical medicine · 2023Article
- Diagnosis and Treatment of Invasive Mold Diseases.Infection & chemotherapy · 2023Review
- Systemic Antifungal Therapy for Invasive Pulmonary Infections.Journal of fungi (Basel, Switzerland) · 2023Review
- Novel Treatment Approach for Aspergilloses by Targeting Germination.Journal of fungi (Basel, Switzerland) · 2022Review
- Therapeutic Approaches for CombatingCurrent drug targets · 2022Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 10 institutions in 3 countries.
Funding
Abstract
backgroundMicafungin (FK463) is a new lipopeptide compound (echinocandin) with activity against Aspergillus and Candida species. This study evaluated the safety and efficacy of micafungin in patients with proven or probable invasive aspergillosis (IA).
methodsA multinational, non-comparative study was conducted to examine proven or probable (pulmonary only) Aspergillus species infection in a wide variety of patient populations. The study employed an open-label design utilizing micafungin alone or in combination with another systemic antifungal agent. Criteria for IA and therapeutic responses were judged by an independent panel.
resultsOf the 331 patients enrolled, only 225 met diagnostic criteria for IA as determined by the independent panel and received at least one dose of micafungin. Patients included 98/225 who had undergone hematopoietic stem cell transplantation (HSCT) (88/98 allogeneic), 48 with graft versus host disease (GVHD), and 83/225 who had received chemotherapy for hematologic malignancy. A favorable response rate at the end of therapy was seen in 35.6% (80/225) of patients. Of those only treated with micafungin, favorable responses were seen in 6/12 (50%) of the primary and 9/22 (40.9%) of the salvage therapy group, with corresponding numbers in the combination treatment groups of 5/17 (29.4%) and 60/174 (34.5%) of the primary and salvage treatment groups, respectively. Of the 326 micafungin-treated patients, 183 (56.1%) died during therapy or in the 6-week follow-up phase; 107 (58.5%) deaths were attributable to IA.
conclusionsMicafungin as primary or salvage therapy proved efficacious and safe in high-risk patients with IA, although patient numbers are small in the micafungin-only groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.